Pentraxin3 in chronic thromboembolic pulmonary hypertension: a new biomarker for screening from remitted pulmonary thromboembolism

PLoS One. 2014 Nov 20;9(11):e113086. doi: 10.1371/journal.pone.0113086. eCollection 2014.

Abstract

Background: Pentraxin3 (PTX3) is a protein, which has multifaceted effects on innate immunity, angiogenesis, and vascular remodeling then could be a disease marker of acute myocardial infarction, heart failure, vasculitis. In addition, PTX3 has been recognized as a biomarker for pulmonary arterial hypertension, however whether it is the case in chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. Therefore, we investigated whether PTX3 would be a useful biomarker for detecting CTEPH with respect to differentiation from stable pulmonary thromboembolism (PTE), in comparison to other biomarkers.

Methods: Plasma PTX3 and brain natriuretic peptide (BNP) levels were measured in 70 patients with CTEPH at their first diagnostic right heart catheterization (CTEPH group) and in 20 patients with clinically stable PTE more than three months after the acute episode (control group). The levels of plasma C-reactive protein (CRP) and heart-type fatty acid-binding protein (H-FABP) were also analyzed to compare the diagnostic ability of these biomarkers.

Results: The mean level of PTX3 (ng/mL) was significantly higher in the CTEPH group than in the control group (5.51±4.53 versus 2.01±0.96, respectively), and PTX3 levels had mild negative correlation with cardiac output. BNP levels were also higher in the CTEPH group and better correlated with pulmonary hemodynamics than PTX3. However, a receiver operating characteristic (ROC) curve showed PTX3 levels were better for detecting CTEPH, and could detect CTEPH patients with less severe pulmonary hemodynamics and low plasma BNP levels. There was no significant increase in CRP and H-FABP levels in the CTEPH patients.

Conclusions: Plasma PTX3 level was the most sensitive biomarker of CTEPH. Although plasma PTX3 levels did not correlate with the severity of the pulmonary hemodynamics compared to BNP, high levels in clinically stable patients following PTE should prompt a further work-up for CTEPH, which may lead to an early diagnosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / blood*
  • C-Reactive Protein / metabolism*
  • Endarterectomy / methods
  • Female
  • Humans
  • Hypertension, Pulmonary / blood*
  • Hypertension, Pulmonary / diagnosis*
  • Hypertension, Pulmonary / surgery
  • Male
  • Middle Aged
  • Natriuretic Peptide, Brain / metabolism
  • Pulmonary Embolism / blood*
  • Pulmonary Embolism / diagnosis*
  • Pulmonary Embolism / surgery
  • ROC Curve
  • Serum Amyloid P-Component / metabolism*

Substances

  • Biomarkers
  • Serum Amyloid P-Component
  • Natriuretic Peptide, Brain
  • PTX3 protein
  • C-Reactive Protein

Grant support

The present study was supported, in part, by a research grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan (https://kaken.nii.ac.jp/d/p/25461148.ja.html) [No. 25461148 awarded to Dr. NT] and a grant to the Respiratory Failure Research Group from the Ministry of Health, Labour and Welfare, Japan (http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/hokabunya/kenkyujigyou/) [H26-076 awarded to Drs. NT SS KT]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.